BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
BridgeBio secured up to $1 billion in convertible preferred equity financing led by Sixth Street and HealthCare Royalty, with $933.9 million funded at close. The Series A preferred stock carries a 7% dividend and an initial conversion price of $137.79 per share, representing a premium of over 100% to the company's 30-day VWAP.
Key figures
- Deal Value Usd
- 1000000000
- Dividend rate
- 7.00%
- Conversion price
- 137.79
- Sixth street investment
- 800000000
- Healthcare royalty investment
- 133900000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.